NEW YORK (GenomeWeb News) — Philips Life Sciences and Organon will perform biomarker studies that could benefit Philips’ imaging programs and Organon's drug-development efforts, the companies said yesterday.
 
Under the agreement, researchers from both companies will use Philips' labs and medical-imaging technologies to identify, validate, and pursue uses for novel biomarkers that Organon may use to develop drug programs for psychiatric and immune system disorders.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.